Greenwich LifeSciences Updates on 10-K Filing
Written by Emily J. Thompson, Senior Investment Analyst
Updated: 7 hours ago
0mins
Source: Newsfilter
- Financial Reporting Progress: Greenwich LifeSciences is currently auditing its 10-K report for the fiscal year ending December 31, 2025, with final approval expected soon, although delays due to auditor coordination issues may impact investor confidence.
- Accounts Payable Adjustments: The company reported significant increases in accounts payable due to unexpectedly high patient screening and enrollment in clinical trials in Europe during 2024 and 2025, but believes these adjustments do not materially affect its financial fundamentals.
- Cash Flow Status: As of March 31, 2026, the company reported a cash balance of approximately $10.5 million, an improvement over 2025, and has retired over 75% of its accounts payable, indicating positive progress in financial management.
- Clinical Trial Data: In the FLAMINGO-01 trial, over 1,300 patients have been screened, with preliminary analysis showing a 70-80% reduction in recurrence rates in the non-HLA-A*02 arm after completing the Primary Immunization Series, indicating the potential efficacy of GLSI-100.
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy GLSI?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
Analyst Views on GLSI
Wall Street analysts forecast GLSI stock price to rise
2 Analyst Rating
2 Buy
0 Hold
0 Sell
Moderate Buy
Current: 26.175
Low
45.00
Averages
47.50
High
50.00
Current: 26.175
Low
45.00
Averages
47.50
High
50.00
About GLSI
Greenwich LifeSciences, Inc. is a clinical-stage biopharmaceutical company focused on the development of GP2, an immunotherapy to prevent breast cancer recurrences in patients who have previously undergone surgery. GP2 is a 9-amino acid transmembrane peptide of the human epidermal growth factor receptor 2 (HER2) /neu protein, a cell surface receptor protein that is expressed in a variety of common cancers. It has commenced a Phase III clinical trial, Flamingo-01, an immunotherapy to prevent breast cancer recurrences. GP2 is delivered in combination with granulocyte-macrophage colony-stimulating factor (GM-CSF) to induce GP2 peptide-specific immunity. GP2 treatment is administered via an intradermal injection by mixing GP2 peptide and GM-CSF at the time of administration. Its cancer immunotherapy seeks to stimulate an individual's immune system to selectively attack cancer cells while not affecting normal cells or to deliver immune system components to inhibit the spread of cancer.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
Greenwich LifeSciences Updates on 10-K Filing
- Financial Reporting Progress: Greenwich LifeSciences is currently auditing its 10-K report for the fiscal year ending December 31, 2025, with final approval expected soon, although delays due to auditor coordination issues may impact investor confidence.
- Accounts Payable Adjustments: The company reported significant increases in accounts payable due to unexpectedly high patient screening and enrollment in clinical trials in Europe during 2024 and 2025, but believes these adjustments do not materially affect its financial fundamentals.
- Cash Flow Status: As of March 31, 2026, the company reported a cash balance of approximately $10.5 million, an improvement over 2025, and has retired over 75% of its accounts payable, indicating positive progress in financial management.
- Clinical Trial Data: In the FLAMINGO-01 trial, over 1,300 patients have been screened, with preliminary analysis showing a 70-80% reduction in recurrence rates in the non-HLA-A*02 arm after completing the Primary Immunization Series, indicating the potential efficacy of GLSI-100.
See More
Greenwich LifeSciences Reports Positive Phase 3 Data for Breast Cancer Vaccine
- Clinical Trial Results: Greenwich LifeSciences presented positive Phase 3 FLAMINGO-01 data at ASCO, indicating that GLSI-100 achieved a 70%-80% reduction in recurrence rates among non-HLA-A*02 subjects, establishing a strong foundation for future market promotion.
- Vaccine Composition and Mechanism: GLSI-100 is an investigational cancer vaccine containing GP2 peptide and Granulocyte Macrophage-stimulating factor (GM-CSF), aimed at preventing metastasis through immunotherapy targeting HER2+ breast cancer, showcasing its potential in tumor immunotherapy.
- New Testing Arm Progress: A new testing arm of approximately 250 non-HLA-A*02 patients has completed enrollment, evaluating GLSI-100 administered via 6 intradermal injections over 6 months and 5 subsequent boosters over 2.5 years, further validating its immune response.
- Market Reaction: GLSI is currently trading at $27.73, up 5.94%, reflecting positive investor sentiment towards the clinical data of the vaccine, which may drive further growth in the biopharmaceutical sector.
See More
Greenwich LifeSciences Updates Financial Status Amid Nasdaq Filing Delay
- Financial Status Update: Greenwich LifeSciences reported that the delay in its 2025 annual report audit does not materially affect its cash position, with an unaudited cash balance of approximately $10.5 million as of March 31, 2026, ensuring business fundamentals remain stable.
- Clinical Trial Progress: The company is conducting the Flamingo-01 trial for GLSI-100, having screened over 1,300 patients, with preliminary data indicating a 70% to 80% reduction in breast cancer recurrence rates after the initial six-dose treatment series, showcasing promising therapeutic potential.
- Nasdaq Compliance Notice: Greenwich received a compliance notice from Nasdaq on April 22, 2026, for failing to file its annual Form 10-K on time, with subsequent notices indicating ongoing audits involving accounts payable adjustments related to patient screening and enrollment.
- Positive Investor Sentiment: Retail sentiment on Stocktwits remains bullish with extremely high message volumes, and the stock has gained nearly 24% year-to-date, reflecting strong market interest and confidence in the Flamingo trial.
See More
Greenwich LifeSciences Receives Nasdaq Notification on Compliance
- Compliance Notification: Greenwich LifeSciences (GLSI) received a notification from Nasdaq on Friday indicating non-compliance with listing rules due to the late filing of its Quarterly Report on Form 10-Q for the three months ended March 31, 2026, although the notice does not have an immediate effect on the listing or trading of the company's common stock.
- Impact of Filing Delay: The failure to submit the quarterly report on time may affect investor confidence, leading to concerns about the company's future financial transparency, which could exert negative pressure on the stock price.
- Market Reaction: Despite the compliance notification, the market's response to Greenwich LifeSciences has been relatively stable, indicating that investor confidence in the company's fundamentals has not been significantly impacted.
- Future Outlook: The company must resolve the compliance issue promptly to avoid further regulatory actions and ensure its continued listing on Nasdaq, thereby maintaining investor trust and market reputation.
See More
Greenwich LifeSciences Receives Nasdaq Notification Regarding 10-K Filing
- Nasdaq Compliance Notification: Greenwich LifeSciences received a notification from Nasdaq indicating non-compliance due to the failure to file its 10-K report for the fiscal year ending December 31, 2025, although this notice does not have an immediate impact on the listing or trading of its stock.
- Stock Trading Status: The company's common stock continues to trade on the Nasdaq Capital Market under the symbol 'GLSI', indicating that despite compliance issues, the liquidity of its shares remains unaffected in the market.
- Future Plans: The company intends to file its 10-K for the fiscal year 2025 as soon as possible, demonstrating a proactive approach to resolving compliance issues and aiming to restore full compliance with Nasdaq regulations.
- Investor Attention: Despite facing compliance challenges, recent open-label data and patent claims from Greenwich LifeSciences continue to attract investor interest, which may influence its future market performance.
See More
Greenwich LifeSciences Expands Vaccine Trial to Broader Patient Population
- Trial Expansion Plans: CEO Snehal Patel announced that the FDA has reviewed plans to expand the trial to include all patient types, with over 1,300 patients enrolled, indicating a significant market opportunity for the breast cancer vaccine.
- Significant Immune Response Increase: Data presented at the 2026 AACR Annual Meeting revealed that the vaccine candidate GLSI-100 showed nearly a 4-fold increase in immune response in non-HLA-A*02 patients, with some patients improving by 2 to 8 times, demonstrating its broader applicability.
- Clinical Trial Results: In the Phase III FLAMINGO-01 trial, delayed-type hypersensitivity (DTH) responses in the specific HLA-A*02 patient cohort increased fourfold from month 4 to 6 of treatment, indicating significant immune activation by the vaccine.
- Positive Market Reaction: Shares of Greenwich LifeSciences rose over 2% in premarket trading on Monday, and the stock has increased by over 28% year-to-date, reflecting bullish sentiment among retail investors regarding the company's prospects.
See More
Greenwich LifeSciences Updates on 10-K Filing
- Financial Reporting Progress: Greenwich LifeSciences is currently auditing its 10-K report for the fiscal year ending December 31, 2025, with final approval expected soon, although delays due to auditor coordination issues may impact investor confidence.
- Accounts Payable Adjustments: The company reported significant increases in accounts payable due to unexpectedly high patient screening and enrollment in clinical trials in Europe during 2024 and 2025, but believes these adjustments do not materially affect its financial fundamentals.
- Cash Flow Status: As of March 31, 2026, the company reported a cash balance of approximately $10.5 million, an improvement over 2025, and has retired over 75% of its accounts payable, indicating positive progress in financial management.
- Clinical Trial Data: In the FLAMINGO-01 trial, over 1,300 patients have been screened, with preliminary analysis showing a 70-80% reduction in recurrence rates in the non-HLA-A*02 arm after completing the Primary Immunization Series, indicating the potential efficacy of GLSI-100.
See More
Greenwich LifeSciences Reports Positive Phase 3 Data for Breast Cancer Vaccine
- Clinical Trial Results: Greenwich LifeSciences presented positive Phase 3 FLAMINGO-01 data at ASCO, indicating that GLSI-100 achieved a 70%-80% reduction in recurrence rates among non-HLA-A*02 subjects, establishing a strong foundation for future market promotion.
- Vaccine Composition and Mechanism: GLSI-100 is an investigational cancer vaccine containing GP2 peptide and Granulocyte Macrophage-stimulating factor (GM-CSF), aimed at preventing metastasis through immunotherapy targeting HER2+ breast cancer, showcasing its potential in tumor immunotherapy.
- New Testing Arm Progress: A new testing arm of approximately 250 non-HLA-A*02 patients has completed enrollment, evaluating GLSI-100 administered via 6 intradermal injections over 6 months and 5 subsequent boosters over 2.5 years, further validating its immune response.
- Market Reaction: GLSI is currently trading at $27.73, up 5.94%, reflecting positive investor sentiment towards the clinical data of the vaccine, which may drive further growth in the biopharmaceutical sector.
See More
Greenwich LifeSciences Updates Financial Status Amid Nasdaq Filing Delay
- Financial Status Update: Greenwich LifeSciences reported that the delay in its 2025 annual report audit does not materially affect its cash position, with an unaudited cash balance of approximately $10.5 million as of March 31, 2026, ensuring business fundamentals remain stable.
- Clinical Trial Progress: The company is conducting the Flamingo-01 trial for GLSI-100, having screened over 1,300 patients, with preliminary data indicating a 70% to 80% reduction in breast cancer recurrence rates after the initial six-dose treatment series, showcasing promising therapeutic potential.
- Nasdaq Compliance Notice: Greenwich received a compliance notice from Nasdaq on April 22, 2026, for failing to file its annual Form 10-K on time, with subsequent notices indicating ongoing audits involving accounts payable adjustments related to patient screening and enrollment.
- Positive Investor Sentiment: Retail sentiment on Stocktwits remains bullish with extremely high message volumes, and the stock has gained nearly 24% year-to-date, reflecting strong market interest and confidence in the Flamingo trial.
See More
Greenwich LifeSciences Receives Nasdaq Notification on Compliance
- Compliance Notification: Greenwich LifeSciences (GLSI) received a notification from Nasdaq on Friday indicating non-compliance with listing rules due to the late filing of its Quarterly Report on Form 10-Q for the three months ended March 31, 2026, although the notice does not have an immediate effect on the listing or trading of the company's common stock.
- Impact of Filing Delay: The failure to submit the quarterly report on time may affect investor confidence, leading to concerns about the company's future financial transparency, which could exert negative pressure on the stock price.
- Market Reaction: Despite the compliance notification, the market's response to Greenwich LifeSciences has been relatively stable, indicating that investor confidence in the company's fundamentals has not been significantly impacted.
- Future Outlook: The company must resolve the compliance issue promptly to avoid further regulatory actions and ensure its continued listing on Nasdaq, thereby maintaining investor trust and market reputation.
See More
Greenwich LifeSciences Receives Nasdaq Notification Regarding 10-K Filing
- Nasdaq Compliance Notification: Greenwich LifeSciences received a notification from Nasdaq indicating non-compliance due to the failure to file its 10-K report for the fiscal year ending December 31, 2025, although this notice does not have an immediate impact on the listing or trading of its stock.
- Stock Trading Status: The company's common stock continues to trade on the Nasdaq Capital Market under the symbol 'GLSI', indicating that despite compliance issues, the liquidity of its shares remains unaffected in the market.
- Future Plans: The company intends to file its 10-K for the fiscal year 2025 as soon as possible, demonstrating a proactive approach to resolving compliance issues and aiming to restore full compliance with Nasdaq regulations.
- Investor Attention: Despite facing compliance challenges, recent open-label data and patent claims from Greenwich LifeSciences continue to attract investor interest, which may influence its future market performance.
See More
Greenwich LifeSciences Expands Vaccine Trial to Broader Patient Population
- Trial Expansion Plans: CEO Snehal Patel announced that the FDA has reviewed plans to expand the trial to include all patient types, with over 1,300 patients enrolled, indicating a significant market opportunity for the breast cancer vaccine.
- Significant Immune Response Increase: Data presented at the 2026 AACR Annual Meeting revealed that the vaccine candidate GLSI-100 showed nearly a 4-fold increase in immune response in non-HLA-A*02 patients, with some patients improving by 2 to 8 times, demonstrating its broader applicability.
- Clinical Trial Results: In the Phase III FLAMINGO-01 trial, delayed-type hypersensitivity (DTH) responses in the specific HLA-A*02 patient cohort increased fourfold from month 4 to 6 of treatment, indicating significant immune activation by the vaccine.
- Positive Market Reaction: Shares of Greenwich LifeSciences rose over 2% in premarket trading on Monday, and the stock has increased by over 28% year-to-date, reflecting bullish sentiment among retail investors regarding the company's prospects.
See More
